Check for updates

RESEARCH ARTICLE

Thousands of exon skipping events differentiate among splicing patterns in sixteen human tissues [version 1; peer review: 2 approved]

Liliana Florea^{1,2}, Li Song^{1,3}, Steven L Salzberg ^{1,2,4}

¹Center for Computational Biology, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

²Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA

³Department of Computer Science, Johns Hopkins University, Baltimore, MD, 21205, USA

⁴Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, 21205, USA

v1 First published: 16 Sep 2013, 2:188
<https://doi.org/10.12688/f1000research.2-188.v1>

Latest published: 21 Nov 2013, 2:188
<https://doi.org/10.12688/f1000research.2-188.v2>

Abstract

Alternative splicing is widely recognized for its roles in regulating genes and creating gene diversity. However, despite many efforts, the repertoire of gene splicing variation is still incompletely characterized, even in humans. Here we describe a new computational system, ASprofile, and its application to RNA-seq data from Illumina's Human Body Map project (>2.5 billion reads). Using the system, we identified putative alternative splicing events in 16 different human tissues, which provide a dynamic picture of splicing variation across the tissues. We detected 26,989 potential exon skipping events representing differences in splicing patterns among the tissues. A large proportion of the events (>60%) were novel, involving new exons (~3000), new introns (~16000), or both. When tracing these events across the sixteen tissues, only a small number (4-7%) appeared to be differentially expressed ('switched') between two tissues, while 30-45% showed little variation, and the remaining 50-65% were not present in one or both tissues compared. Novel exon skipping events appeared to be slightly less variable than known events, but were more tissue-specific. Our study represents the first effort to build a comprehensive catalog of alternative splicing in normal human tissues from RNA-seq data, while providing insights into the role of alternative splicing in shaping tissue transcriptome differences. The catalog of events and the ASprofile software are freely available from the Zenodo repository (<http://zenodo.org/record/7068>; doi:10.5281/zenodo.7068) and from our web site <http://ccb.jhu.edu/software/ASprofile>.

Open Peer Review

Approval Status

	1	2
version 2		
(revision)
21 Nov 2013
version 1		
16 Sep 2013

1. **Manuel Corpas** , The Genome Analysis Center, Norwich, UK

2. **Peter N. Robinson**, Universitätsklinikum Charité, Berlin, Germany

Any reports and responses or comments on the article can be found at the end of the article.

This article is included in the **Bioinformatics** gateway.

Corresponding author: Liliana Florea (florea@jhu.edu)

Competing interests: No competing interests were disclosed.

Grant information: This work was supported in part by the NSF award ABI-1159078 to LF and NIH grants R01-HG006677 and R01-HG006102 to SLS.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2013 Florea L *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Florea L, Song L and Salzberg SL. **Thousands of exon skipping events differentiate among splicing patterns in sixteen human tissues [version 1; peer review: 2 approved]** F1000Research 2013, 2:188 <https://doi.org/10.12688/f1000research.2-188.v1>

First published: 16 Sep 2013, 2:188 <https://doi.org/10.12688/f1000research.2-188.v1>

Background

Alternative splicing is a widespread phenomenon in eukaryotic species, and differential regulation of alternative splice variants is gaining recognition as an important mechanism of gene regulation. More than 90% of human genes are estimated to be alternatively spliced^{1,2}, producing multiple transcripts and (often) different protein sequences from a single locus. The number of variants of a gene ranges from two to potentially thousands³. The resulting proteins may exhibit different and sometimes antagonistic functional and structural properties⁴, and may inhabit the same cell with the resulting phenotype representing a balance between their expression levels⁵. Defects in splicing have been implicated in human diseases, including cancer^{6–9}. Developing a comprehensive catalog of splice variant annotations across a wide range of tissues and conditions is important not only as part of our efforts to create a complete gene list for the human genome, but also to serve as a reference for differential expression studies aiming to identify molecular markers of disease.

Annotation of alternative splicing has traditionally been based on cDNA (expressed sequence tags (EST), mRNA) sequence data from public repositories such as dbEST, RefSeq¹⁰, and the Mammalian Gene Collection¹¹. These data sources were compiled over many years, from independent contributions by thousands of investigators working on different genes and systems, and are therefore inconsistent in their coverage of the transcriptome in general and of each gene individually. Because these resources were generated using Sanger sequencing, they were relatively expensive to produce, but despite the cost have insufficient depth to capture the diversity of splicing variations in human cells. RNA-seq technology produces vastly more sequence data in a cost-effective way and in a much shorter amount of time, allowing a deep characterization of the transcriptome in a variety of cells and conditions^{2,12,13}, but so far little has been done to systematically assess its potential¹⁴. Starting from one of the most complete sets of RNA-seq data available, the Illumina Human Body Map, we addressed the questions: “how much alternative splicing do we find?” and “how does alternative splicing vary among tissues?” We used this data set, spanning 16 tissues and containing over 2.5 billion sequences, to build a comprehensive catalog of alternative splicing (AS) within each tissue. We also compared AS profiles across tissue types to derive insights into the role of AS in shaping transcriptome differences.

Results

We analyzed the Illumina Human Body Map RNA-seq set (ArrayExpress accession: E-MTAB-513; <http://www.ebi.ac.uk/arrayexpress>), consisting of approximately 160 million reads from each of 16 tissues, each from a different individual. This resource is one of the most high-quality and complete to date, and therefore allows us to detect AS events with high accuracy. To determine splicing variations in each tissue, we first mapped reads to the reference genome and assembled them into transcripts or transcript fragments. We then analyzed the transcripts to determine putative alternative splicing events, in particular exon skipping events, within and between samples, and compared them across the tissues. We focused on exon skipping because the alignment evidence for these events is usually clear and unambiguous, and less likely to be confounded

by alignment or assembly artifacts. The data support a number of overall findings:

1. Based on a comparison against several annotation databases (Ensembl¹⁵, CCDS¹⁶, UCSC Genes¹⁷ and H-ASDB¹⁸), we found that 11–45% of the assembled transcripts in each tissue were unannotated, as well as a majority (65%) of the 26,989 exon skipping events discovered from this data set.
2. These novel events appear to be more tissue-specific than previously annotated (known) events; i.e., they tend to occur in fewer tissue types.
3. When an exon is skipped, it usually occurs in a different tissue from those in which it is present; only 5–23% of events express both forms within the same tissue.
4. Comparing exon skipping profiles across tissues, we found that only 10–20% of the events identified show different splicing ratios between any two given tissues, whereas 50–65% of the cataloged events are not present in either or both tissues.

Overall, our analysis reveals a complex and dynamic picture of alternative splicing across tissue types, where differences among tissue transcriptomes arise from the interplay between constitutive transcription and alternative splicing. Most importantly, we compiled the first large repository of putative exon skipping and other classes of alternative splicing events in normal human tissues detected from RNA-seq data, which will be a valuable resource for studies of regulation and to identify markers of diseases. This catalog and our methods, implemented in the open source software program ASprofile, are freely available from the Zenodo repository (<http://zenodo.org/record/7068>; doi:10.5281/zenodo.7068) and from our web site <http://ccb.jhu.edu/software/ASprofile>.

A global view of alternative splicing in the 16 tissues

To determine alternative splicing events and globally characterize alternative splicing within a given tissue, we analyzed 50-bp paired-end sequences from 16 different tissues: adrenal, adipose, brain, breast, colon, heart, kidney, liver, lung, lymph, ovary, prostate, skeletal muscle, testes, thyroid and white blood cells. These data are publicly available as the Illumina Human Body Map project (EMBL accession ENA-ERP000546; ArrayExpress accession: E-MTAB-513; <http://www.ebi.ac.uk/arrayexpress/browse.html?keywords=E-MTAB-513&expand=on>). Libraries were made from polyA-selected mRNA with an insert size of 210 bp, independently for each tissue, using a random priming process and unstranded. One run of 2x50 bp paired-end sequencing was performed on the Illumina HiSeq2000 instrument, using one lane per tissue, to produce approximately 80 million pairs of reads (160 million sequences) per tissue. The entire data set comprises ~128 gigabases (GB) of sequence (~8 GB sequence per tissue), making this one of the most complete RNA-seq resources to date and one of very few spanning multiple types of tissues.

We mapped reads to the human genome with the program TopHat¹⁹ (Supplemental Table S1), and then assembled overlapping reads on the genome into transcript fragments using Cufflinks²⁰. Cufflinks represents all reads at a locus as an assembly graph, in which any two reads are connected if they overlap and have compatible splice patterns, and

then traverses the graph to produce the minimum number of transcripts that can explain all of the input reads. Because single-exon transcripts, which form the bulk of the assemblies (Figure 1 and Supplemental Table S2), are frequently artifacts of sequencing and mapping, we used only the multi-exon transcripts to measure the gene and transcript content.

Although the assemblies produced by Cufflinks can be full-length transcripts, many transcripts can only be assembled into partial fragments (e.g., when the coverage of a transcript contains gaps). We therefore designate all transcript assemblies, complete or otherwise, as *transfrags*. For each tissue, Cufflinks produced between 23,000–46,000 multi-exon transfrags, clustered into 20,000–30,000 loci. The number of transfrags was greatest in brain and testes, and lowest in liver, colon, white blood cells and skeletal muscle, reflecting the combined effects of the number of expressed genes (Pearson's $r^2=0.74$) and splicing variation within genes. These findings are consistent with some of the earlier estimates of the sizes of transcriptomes of different tissues^{1,21–25}. To estimate the number of novel splice forms, we compared the assemblies to a known annotation database, Ensembl¹⁵, using the program Cuffcompare from

the Cufflinks package. This gave us between 35,000–52,000 transfrags per tissue that were associated with 13,000–17,000 Ensembl genes, of which a large fraction (between 5,000–20,000 per tissue, representing 11–45% of the total) appeared to be novel splice forms (Figure 1, Supplemental Figure S3 and Supplemental Table S3). Tissues with large numbers of new splice forms also had a larger fraction of candidate new splice forms.

Even with the best data and software, computational reconstruction of long transcripts from short reads is prone to assembly errors. We therefore focused on classes of alternative splicing events that are most likely to be assembled correctly. Exon skipping events are the most prevalent type of alternative splicing events in the human genome²⁶, and are particularly easy to identify from transcript data and less likely to be mis-assembled. They have been extensively studied and are well represented in the databases. For these reasons, exon skipping events provide an excellent proxy for the number of other types of splicing variants in a sample.

We define an exon skipping 'event' as a pairing between an exon-containing form ('on') and an exon-excluding form ('off'), occurring

Figure 1. A high-level view of alternative splicing in sixteen human tissues: numbers of multi-exon 'genes' and transcripts from *de novo* transcript assemblies produced by Cufflinks (left), and by Cuffcompare (right). Since Cufflinks may break transcripts and genes into multiple fragments when there is insufficient read coverage, we used Cuffcompare to compare transfrags against the Ensembl reference annotations to produce a better estimate for the number of genes and transcripts in the samples. Results in the right panel show the total number of Ensembl annotated as well as novel genes, and respectively transcripts, found in each sample. The number of novel isoforms identified by Cuffcompare is shown in the bottom panel.

at the same exon and with the same flanking introns. The same exon (or intron) may be involved in multiple exon skipping events, though the number of such cases is small. To generate a catalog of events for the sixteen tissues, we analyzed transcript assemblies using our software ASprofile and identified differences in exon-intron structures characteristic of the various classes.

We found over 150,000 candidate alternative splicing events (Supplemental Table S4). Among these, we found 26,989 exon skipping events at 25,017 distinct exons, involving 22,145 distinct introns. Almost all of these events (25,920) were found in comparisons between different tissues, although a significant fraction (16,382) were also found when comparing isoforms within the same tissue. There were 1,069 instances of alternative splicing events that were restricted to a single tissue, most of them in testes (416) and brain (172).

Mapping artifacts can create false exon skipping events, due to incorrect or duplicated splice junctions or incorrectly reconstructed exons. To assess the accuracy of the data set and identify potential artifacts for future curation, we first looked for co-located events that showed small variations (≤ 5 bp) at exon and intron boundaries, which could be caused by imprecise mapping of spliced reads. Such variations could lead to redundancy in reporting the events. For reference, we compared the extent of variation against the ENSEMBL gene annotations. There were 1,822 (6.75%) events in our data set that represented slight variations of other events compared to 427 (1.7%) in the ENSEMBL data, suggesting that up to 5% of events in our data set may be redundant (Supplemental Figure S5 and Supplemental Table S5). However, this figure is likely an overestimate, given that small 5' and 3' exon splicing variations are hard to detect with conventional (Sanger) data and are likely underrepresented in the reference gene annotations. We also evaluated the reproducibility of our results when using other transcript assembly methods (IsoCEM²⁷, SLIDE²⁸, and Scripture²⁹), in a second test. We found that 84% (2,471 out of 2,934) of exon skipping events found in the adrenal sample alone were independently discovered when using one of the other transcript assembly methods (Supplemental Table S6). When aggregating data across the sixteen tissues, 92% (24,936) of the introns spanning skipped exons have at least two reads supporting them in the sixteen tissues; although in general exon-skipping introns have fewer supporting reads than other introns (Supplemental Figure S7). Similarly, in 21,469 (80%) of the exon skipping events, the exon was present in two or more tissues. Thus, while some assembly artifacts could still be present, most of the events discovered have strong supporting evidence.

How much alternative splicing is novel?

Simply counting the number of transcripts assembled from RNA-seq data is one way to measure the extent of alternative splicing. However, this can be confounded by transcripts that are assembled incompletely or incorrectly. Exon skipping events are discrete and easily counted, although it is worth noting that a given exon might be skipped in multiple distinct transcripts. To avoid the difficulties of counting all splice variants, we used the number of exon skipping events as a surrogate measure of splicing variation.

To identify which of the splice variants were previously unreported, we searched the 26,989 skipped exon events against four gene annotations databases: CCDS¹⁶ (23,353 sequences) (<http://genome.ucsc.edu>, download May 2011), UCSC Genes¹⁷ (73,671) (<http://genome.ucsc.edu>, download May 2011), Ensembl v.61 (120,122) (<http://ensembl.org>), and H-DBAS¹⁸ (58,609 mRNA and 37,096 fl-cDNA RASVs) (<http://h-invitational.jp/h-dbas/>, download May 2011). Importantly, these specific data sets and releases had been produced using almost exclusively traditional cDNA (EST, mRNA) resources, and therefore provide a fairly accurate assessment of the potential to discover novel alternative splicing variation in RNA-seq experiments. We found that over 60% (17,442) of the events were novel, even after allowing for slight differences in the annotation of exon boundaries present in the various databases (Supplemental Table S8). New exons, new introns, or both can lead to novel splicing events, but we discovered novel introns much more frequently than novel exons (2,914 exons and 15,958 introns). The majority of novel exons overlap known exons; i.e., one or both exon boundaries are novel, but not the entire exon. 884 exons did not overlap any previously annotated exon. A total of 996 (34.2%) of the novel exons and 3,801 (23.8%) of the novel introns were also supported by EST alignments, which provides independent cDNA evidence for those events.

One example of a novel event is shown in Figure 2. CHTOP (Chromatin target of Prmt1, synonym FOP) is a small nuclear protein on chromosome 1 characterized by an arginine- and glycine-rich region. It has a role in ligand-dependent activation repression of an estrogen receptor target gene³⁰, and has been shown to be a critical modulator of gamma-globin gene expression³¹. The 84 bp in-frame exon at chromosome 1 positions 153,611,844–153,611,927, which we observed only in heart tissue, does not overlap any of the annotated structures for this gene and has only weak EST evidence, in the terminal exon of EST DB270513. However, the entire exonic region is highly conserved in placental mammals, strongly suggesting that this region is part of the spliced gene. Further, DNaseI hypersensitive sites lend support to an alternative transcript starting at this exon in thyroid tissue. This alternative transcription start site was also identified by our method, and is also missing from the annotation.

Another novel event occurs in the gene ASB15 (ankyrin repeat and SOCS box containing 15) (Supplemental Figure S9). Human ASB15 is known to be expressed predominantly in skeletal muscle and to participate in the regulation of protein turnover and muscle cell development by stimulating protein synthesis and regulating differentiation of muscle cells. Bovine ASB15 mRNA was also found in heart and pituitary gland tissue, and rat ASB15 was additionally present in kidney and lung tissue, but the amount in most other tissues analyzed was scarce³². These results are consistent with the Illumina Human Body Map data set. Here, exon chr7:123,257,633–123,257,718 is a novel shorter variant that shares its 5' end with the annotated exon. Both the exon-containing and the exon skipping form are expressed in heart, and have strong read support in the 16 tissues (136 and 39 reads supporting the flanking introns, and 30 reads spanning the exon). Evidence for the novel splice junction is also present in skeletal muscle tissue. We

Figure 2. A novel alternatively spliced exon (chr1: 153,611,844–153,611,927) at the *CHTOP* gene locus, which does not overlap any known annotation. This novel 84-bp exon, marked with a red circle in the figure, is the 4th exon in one of the transcripts from heart tissue (heart.79763.3), and it appears exclusively in that tissue, although a partial form is present in a skeletal muscle transcript.

also found a novel putative intron retention event (chr7:123269489–123270019, 531 bp) whose sequence is conserved across multiple vertebrate species. Overall, our analyses underscore the vast potential for RNA-seq experiments to unearth novel splicing events and isoforms.

Characterization of exon skipping events

We next sought to characterize the set of exon skipping events within and across the sixteen tissues, which also offers a glimpse into the dynamics of alternative splicing in these tissues. We separately traced the presence of the two forms ('on' and 'off') to generate an alternative splicing profile for each tissue. For each event, we determined the exon inclusion ratio from the expression levels of isoforms containing the 'on' and the 'off' forms in that tissue: $R = \text{FPKM}_{\text{on}} / (\text{FPKM}_{\text{on}} + \text{FPKM}_{\text{off}})$, and then compared the profiles to determine similarities and changes in splicing patterns among tissues. We used the relative inclusion ratio² to characterize such changes: $\Delta = |R_i - R_j|$, and classified them based on the size of the difference. We separately trace exon skipping events that show large variation ('switches'; $\Delta \geq 0.5$), essentially switching between a minor-form and a major-form, and those that show milder variation. Note that all of these evaluations, based as they are on a single sample from each tissue, provide only a qualitative assessment of variation. Multiple replicates would be required to make any conclusions about the statistical significance of these changes between tissues.

Of the 26,989 exon skipping events, between 10,000–20,000 are present in any given tissue. Most events (77–95%) have only one of the forms expressed in a given tissue, and only 5–23% have both forms present in the same tissue (Figure 3 and Supplemental Table S10). The exon-containing ('on') form is generally prevalent ($R \geq 0.5$). When comparing the profiles between two tissues (Figure 4), 25–35% of the events show stable splicing patterns ($\Delta < 0.1$), 5–10% are variable ($0.1 \leq \Delta < 0.5$) and only 4–7% appear to switch. These proportions are quite similar among the tissues. Roughly 50–65% of the events are not comparable, with the event not found in either or both tissues. Further examination showed these to be due largely to the gene not being expressed (fragments per kilobase of transcript per million mapped (FPKM) < 0.1) or harboring different splice forms, whereas we expect the number of incomparable events caused by computational artifacts to be very low. A significant portion of these genes were expressed at low-to-medium levels (FPKM ≤ 10.0), which makes reconstruction difficult and may cause the event to be missed. (For an example, the comparison between the adrenal and adipose tissues is shown in Supplemental Figure S11). These observations suggest that both transcription and alternative splicing contribute significantly in shaping the transcriptomic differences among tissues, although more complete data sets and experiments are needed to be able to tease apart their specific contributions.

Characterization of novel events

We contrasted known and newly found events to determine characteristics that could have made the latter difficult to discover with conventional (Sanger) data and methods, and to derive insights into the types of experiments that can help fill in the gaps in the alternative splicing catalog.

First, we analyzed the variability in splicing patterns of events, distinguishing between 'switches' and events exhibiting milder

variation. There was a slight but statistically significant difference between the distributions of novel and known events (chi-square 274.7; $p=0.0$; Supplemental Table S12), with switches representing 69% of the known events and only 59% of the novel set.

Second, we assessed the tissue specificity of known and newly found exons and introns based on the data available (Figure 5). For this test, we binned both the known and the novel features according to the number of tissues in which they were found. Not surprisingly, novel exons and introns were significantly more likely to appear in a small number of tissues compared to their known counterparts, but the prevalence was remarkable for exons. For instance, while novel introns were more likely to belong to a single tissue by a 3.0:1 margin (48% versus 16%), that margin for exons was 5:1 (71% versus 14%). Considering that our search turned out many more novel introns than exons, this observation suggests that targeted studies will be needed in the future to identify these highly tissue-specific exons.

Discussion

Alternative splicing is a widely recognized RNA processing mechanism in eukaryotic species, playing a major role in the molecular biology of the cell, and within humans it has been implicated in multiple genetic disorders³³. The Human Genome Project created an initial map of splice variation more than a decade ago^{34,35}. However, despite concerted efforts over the following years, this map is still inaccurate and incomplete. The Ensembl annotation¹⁵, which is among the most complete to date, currently contains seven variants on average per protein coding gene. This is likely an underestimate, as more variants are added every day. The challenge of cataloging all alternative splice variants is daunting, considering that every tissue and cell type can have a different transcriptome, further differentiated by the condition of the cell at the time it was surveyed.

Unlike traditional methods that have mined heterogeneous cDNA sequences collected over time, RNA-seq experiments can survey the transcriptome of a cell type or tissue at great depth, allowing characterization of alternative splicing in much finer detail than previously. The main drawback to RNA-seq today is that its shorter reads are more challenging to assemble into long isoforms. To avoid some of the uncertainty associated with transcriptome assembly, we focused here on alternative splicing events within a transcript, each of which can be detected with a single read.

We found over 150,000 candidate alternative splicing events, including roughly 27,000 exon skipping events, most of which (65%) were novel. New introns (15,958) were the main source of novel events in our data set, but we also found a large number of new exons (2,914). A large majority of the new exons appear to be tissue-specific, with 71% present in only one tissue, which may explain why they have not been detected previously. Tissue-specific exons represent a clear and important contribution of alternative splicing to tissue differentiation, hence it is noteworthy that 2,085 (38%) of the 5,520 events in our data set were newly identified in this study. Both novel exons and novel introns were more likely to be tissue-specific than those already in the public annotation sets. This suggests that targeted experiments in different tissues or cellular conditions will be more productive in identifying novel splice

Figure 3. Splicing variation at skipped exon events as measured by the exon inclusion ratio $R = \text{FPKM}_{\text{on}} / (\text{FPKM}_{\text{on}} + \text{FPKM}_{\text{off}})$ in the sixteen tissues. Most events within a given tissue are single variant (top). When both isoforms are present in a tissue, the exon is typically contained in the major form ($R \geq 0.5$) (bottom).

forms in the future. This requirement is particularly relevant for identifying new exons, which have already been surveyed quite intensively, whereas even broad range RNA-seq experiments remain a rich source of new introns.

Our analysis of the 27,000 events across the sixteen tissues has also revealed insights into the dynamics of the alternative splicing repertoire and its role in tissue differentiation. With roughly 10–20% of the events showing variation across the tissues and 50–65% incomparable

based on the existing data, the picture of alternative splicing contributions to tissue transcriptome differentiation vis-à-vis transcription is shaping up to be significant, albeit incomplete. Indeed, even in a deep and rich data set such as the Illumina Human Body Map, rare splice forms may be poorly represented or can be missed entirely. Also, our analyses here are based on a single experiment per tissue from a single individual, and therefore we cannot rule out polymorphic variation, although we expect its contribution to be small relative to tissue related differences^{2,14}. Of course, experimentally testing the events³⁶ and

Figure 4. Splicing patterns for the 26,989 exon skipping events are compared between any two tissues, and events are classified by the difference in the splicing ratios. The 255 x 255 matrix shows the dynamics of exon skipping events between a tissue and each of the others. The numbers of similar (blue), variable (green), switch (purple) and not present (red) events between any two tissues are shown along one line.

replication on multiple biological samples, from different individuals, will be essential for full validation.

While there are ongoing efforts to incorporate alternative splicing information from RNA-seq data into gene annotation databases³⁷, there is yet no repository specifically for human alternative splicing events. Our analyses have identified thousands of putative alternative splicing events, which we have compiled into a catalog of exon skipping events derived from RNA-seq data from multiple human tissues. This collection will be a valuable resource for investigating the mechanisms and evolution of alternative splicing, and as a complement to existing annotation databases. Although this catalog adds substantially to the list of known alternative splicing events, many more RNA-seq experiments will be needed to fully characterize alternative splicing over the full spectrum of tissue types and cellular conditions. Our methods, as implemented in the ASprofile software, are freely available to allow others to create similar databases for other organisms or experimental systems.

Materials and methods

Sequence data

RNA-seq data for the Illumina Human Body Map Project were downloaded from <http://www.ebi.ac.uk/arrayexpress/browse.html?keywords=E-MTAB-513&expand=on>. For sequencing, samples for each of the 16 tissues (adrenal, adipose, brain, breast, colon, heart, kidney, liver, lung, lymph, ovary, prostate, skeletal muscle, testes, thyroid and white blood cells) were prepared by Illumina using

their mRNA-Seq kit (Part #RS-100-0801). In brief, PolyA+ RNA was purified from 100 ng of total RNA with oligo-dT beads, and then fragmented with divalent cations under elevated temperature. First strand synthesis was performed with random hexamer and reverse transcriptase, and second strand synthesis with RNaseH and DNA PolII. Following cDNA synthesis, the double stranded products were end-repaired, a single "A" was added and then the Illumina PE adaptors were ligated on to the cDNA products. The ligation products were purified using gel electrophoresis. The target size range for these libraries was ~300 bp, such that the final library for sequencing would have cDNA inserts with sizes of ~200 bp long. One run of 2x50 bp paired-end sequencing was performed on the HiSeq2000 instrument, using one lane per tissue, to produce approximately 80 million read pairs per tissue (160 million sequences) (<http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-513/protocols/>).

Reconstructing the tissues' transcriptomes

To determine splice variants within each tissue, we aligned reads to the hg19 genome using TopHat v1.3.3 (parameters '-a 6 -F 0.05 -splice_mismatches=1 -max-multihits=10'). To allow TopHat to detect as many splice junctions as possible, we provided an intron database extracted from the UCSC known Genes data set (<http://genome.ucsc.edu>). Aligned reads were then assembled into transcript fragments using Cufflinks v0.9.3 (parameters '-F 0.05'). We used Cuffcompare to compare these transcripts to the Ensembl v.61 annotation, and then Cuffdiff to redistribute reads along a high-confidence

Figure 5. Distribution of novel and known features by the number of tissues in which they occurred. (A) The percentage of exons found in 1, 2, ..., 16 tissues are shown as horizontal bars, for the 2,914 novel exons ('novel-X') and 24,075 known exons ('known-X'). (B) Similarly for the 15,958 novel introns ('novel-I') and 11,031 known introns ('known-I').

set of transcripts obtained after eliminating likely artifacts and assemblies not associated with Ensembl genes. Cuffcompare classifies assembled transcripts into multiple categories in relation to reference transcripts, including equal, contained, new splice isoform, intron-located, pre-mRNA fragment, repeat, etc. We retained only transcripts that were deemed 'equal', 'contained', or 'new splice isoforms' as part of our high-confidence set for each tissue. FPKM expression level values for this set were then re-estimated from the original alignments using Cuffdiff.

Discovery of alternative splicing events

To determine alternative splicing events, we developed a software package, ASprofile, to analyze all pairs of transcripts in the sixteen tissues to determine exons included in one transcript and skipped in the other. We restricted the analysis to Ensembl genes with $\text{FPKM} \geq 0.1$, re-estimated by Cuffdiff as described above. We define an exon skipping event as a pair between an exon containing ('on') splice form and an exon skipping ('off') splice form, where

the boundaries of the flanking introns are required to match precisely. To determine which events are novel, the exons and spanning introns were compared against several annotation data sets (CCDS, UCSC Genes, Ensembl v.61, H-ASDB and dbEST¹⁰), allowing for a small difference (up to $W=5$ bp) at the endpoints. For comparison against ESTs, spliced alignments of all human dbEST sequences were produced with the program ESTmapper³⁸.

Comparison of alternative splicing events across tissues

For each event, we calculated the exon inclusion ratio $R = \text{FPKM}_{\text{on}} / (\text{FPKM}_{\text{on}} + \text{FPKM}_{\text{off}})$ for each tissue, similarly to Wang *et al.*², where FPKM_{on} is the combined FPKM of all isoforms containing the 'on' form, and similarly for FPKM_{off} . To account for minor differences in the annotation of splice junctions, when calculating the expression level of an event we included contributions from splice forms in which the boundaries of the exon and flanking and spanning introns differed slightly ($W \leq 10$) from those of the annotated event. The relative inclusion ratio between two tissues, $\Delta_{ij} = |R_i - R_j|$, was determined for each event and used to classify events based on the size of the differences: stable ($\Delta < 0.1$), variable ($0.1 \leq \Delta < 0.5$), 'switch' ($\Delta \geq 0.5$), or incomparable, when the event was not found in one or both tissues. For the tissue-specificity analysis, the largest difference between any two tissues was used to determine 'switches' versus 'non-switches'.

Implementation

We implemented the methods in a software package, ASprofile, for discovering alternative splicing events in transcripts predicted from RNA-seq data and then comparing them across multiple conditions. ASprofile consists of programs for extracting ('*extract-as*'), quantifying ('*extract-as-fpkm*') and comparing ('*collect-fpkm*') alternative splicing events. '*Extract-as*' takes as input a GTF transcript file, for instance one produced by a transcript assembly program or a set of gene annotations, and compares all pairs of transcripts within a gene to determine exon-intron structure differences that indicate an AS event. The following classes of events are currently implemented: exon skipping, cassette exons, alternative transcript start and termination, retention of single or multiple introns, and alternative exon ends (Supplemental Figure S13). To determine alternative splicing events among multiple samples, a single input file must be created by concatenating the transcript files of individual samples, with the gene names *a priori* reconciled across the samples (for instance, by using the program Cuffcompare from the Cufflinks suite). The second program, '*extract-as-fpkm*', calculates the FPKM of each event from those of transcripts harboring the event in a given sample, allowing for small variations (up to V bp, where V is a user-specified value) at the boundaries of the exons and introns. Lastly, the script '*collect-fpkm*' collects the FPKM event values for all RNA-seq samples, and calculates and compares splicing ratios across samples, which can be used to observe trends in the dynamics of alternative splicing profiles or to select promising candidates for laboratory testing. The software package is written in C and Perl and is available free of charge from the Zenodo repository (<http://zenodo.org/record/7068>; doi:10.5281/zenodo.7068) and from our web site at <http://ccb.jhu.edu/software/ASprofile>.

Author contributions

LF and SLS conceived the project and designed the experiments. LF and LS carried out the computational analyses. LF wrote the first draft, and SLS edited the final version of the manuscript. All authors read and approved the final manuscript.

Competing interests

No competing interests were disclosed.

Grant information

This work was supported in part by the NSF award ABI-1159078 to LF and NIH grants R01-HG006677 and R01-HG006102 to SLS.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgments

We thank Illumina for making available the Human Body Map data set.

Supplementary materials

Table S1. Total number of RNA-seq reads from each of 16 human tissues. "Mapped" refers to the number of reads that had at least one and no more than ten alignments to the genome.

Tissue	Reads	Mapped
Adipose	154,600,144	138,872,338
Adrenal	148,945,742	133,883,290
Brain	147,026,094	134,791,012
Breast	151,724,430	135,987,146
Colon	164,874,886	150,966,150
Heart	165,837,568	155,841,749
Kidney	160,794,674	143,888,751
Liver	160,097,246	149,817,522
Lung	158,593,810	144,039,113
Lymph	164,156,314	146,044,267
Ovary	161,892,520	147,588,256
Prostate	164,668,152	151,847,711
Skeletal muscle	164,222,278	151,847,711
Testes	163,672,398	149,727,704
Thyroid	163,825,774	148,942,521
White blood cell	162,434,296	149,167,286
Total	2,557,366,326	2,333,252,527

Table S2. Overview of results from the Cufflinks transcript assembly process. Cufflinks assembles short reads aligned to a genome into a set of transcript fragments ('transfrags' or 'transcripts' or 'txpts', below), grouped by locus ('gene').

Tissue	Genes*	Multi-exon	Txpts/gene†	Transfrags	Single exon	Multiexon	Exons/txpt‡
Adrenal	307,088	23,135	2.0	357,774	311,766	46,008	5.6
Adipose	134,348	21,793	1.5	158,142	126,207	31,935	6
Brain	239,971	24,435	1.8	218,818	238,497	43,321	6
Breast	191,620	23,553	1.6	222,525	185,869	36,656	5.5
Colon	116,723	23,503	1.3	133,953	103,071	30,882	5.1
Heart	149,951	21,537	1.5	177,059	144,829	32,230	6.5
Kidney	171,862	24,000	1.5	197,742	162,910	34,832	5.4
Liver	95,495	21,228	1.3	110,116	82,732	27,384	5
Lung	172,439	25,176	1.4	194,640	159,123	35,517	4.9
Lymph	188,709	23,766	1.5	216,692	179,938	36,754	4.9
Ovary	210,035	22,949	1.8	252,081	210,391	41,690	6.5
Prostate	161,526	24,584	1.4	186,159	150,732	35,427	5.5
Skel_muscle	95,684	19,695	1.2	105,209	82,359	22,850	4.7
Testes	220,459	29,546	1.6	259,043	212,894	46,169	5.9
Thyroid	187,169	23,357	1.8	224,647	184,751	39,896	6.3
White_blood	98,731	19,943	1.3	113,656	88,538	25,118	5.5

*Genes containing multi-exon transcripts.

†Averaged over multi-exon genes.

‡Averaged over multi-exon transcripts.

Table S3. Novel and known gene splice forms in the sixteen tissues, determined by comparison to the ENSEMBL v.61 annotation database using the program Cuffcompare. Cuffcompare compares each predicted transcript's intron chain against those of the reference transcripts and classifies the transfrag as: 'equal' to a reference transcript, if their intron chains are identical; 'contained', if included in a reference transcript's; or as a 'new splice form', if the intron chain has at least one splice junction in common with the reference transcripts (n.b., other Cuffcompare codes are not relevant and were omitted).

Set	Comparison to ENSEMBL v.61		
	Full-length (Equal)	Partial (Contained)	New splice forms
Adrenal	5,705	22,613	22,592
Adipose	5,593	22,293	11,233
Brain	6,497	20,673	19,329
Breast	5,665	24,190	13,665
Colon	4,689	28,715	9,310
Heart	6,103	17,614	11,701
Kidney	5,501	26,615	11,775
Liver	4,483	24,563	7,692
Lung	4,958	33,735	12,346
Lymph	4,574	33,682	14,364
Ovary	7,017	18,667	18,048
Prostate	5,673	27,183	12,470
Skel_muscle	3,318	33,999	4,999
Testes	7,077	23,648	17,306
Thyroid	6,487	21,098	16,667
White_blood	4,568	25,004	6,533

Figure S3. Proportion of predicted novel splice forms from the total number of transcript assemblies, including novel and known (top), and absolute counts of novel splice forms (bottom) detected in the 16 tissues. Novel and known isoforms are determined by comparison with ENSEMBL v.61 gene annotations using the program Cuffcompare (see caption to Table S3 for more details).

S5. Potential effects of imprecise splice junctions on the exon skipping (ES) estimates

One class of mapping artifacts that can contribute to creating false exon skipping events is that of ‘imprecise splice junctions’, where the same intron in different spliced reads is mapped by the alignment software at slightly different positions, typically within a few bp of each other, thus creating the appearance of several introns at that location. Such variations could lead to redundancies in reporting exon skipping events. To estimate the potential effects of imprecise splice junctions on our data set, we searched the 26,989 events against each other to identify those that are co-located and differ only slightly (by some maximum number of bases, V bp) in their exon-intron boundaries. (Note, however, that such events would also include all *true* alternative 5’ and 3’ exon ends). At each locus, we designate one event as ‘anchor’ (true), and refer to the co-located events as ‘variations’. We repeated the operation for 25,114 events discovered from the Ensembl v. 61 annotation with our software ASprofile, to create a baseline for comparison. For our data set of 26,989 events, labeled ‘Cufflinks’ in Figure S5 below, small ≤ 5 bp differences in splice junctions account for the majority of ES variations, beyond which their value as a fraction of the total number of ES events becomes relatively stable. In contrast, the

Table S4. Numbers of candidate alternative splicing events found in the Illumina Human Body Map data, by type.

Event type	Code	Count
Exon skipping (single exon)	SKIP	26,989
Exon skipping (multiple exons)	MSKIP	13,814
Alternative 5’ terminal exon*	TSS	97,399
Alternative 3’ terminal exon*	TTS	45,609
Intron retention (single intron)	IR	16,671
Intron retention (multiple introns)	MIR	2,636
Alternative exon boundaries	AE	22,767

*Includes 17,200 ‘default’ TSS (TTS) sites for 17,200 genes.

percentage of Ensembl v. 61 event variations continues to increase roughly linearly with the distance from the ‘anchor’ splice junction. Comparing the two curves, we estimate that up to ~1,400 of ES events (5%) in our data set could be redundant (column 10 in the Table S5). We expect this value to be an overestimate, given that true small 5’ and 3’ exon alternative splicing variations are poorly represented in annotation databases.

S6. Reproducibility of exon skipping event discovery with other assembly methods

To assess the reproducibility of our event discovery method, we compared the exon skipping events discovered from transcripts assembled with Cufflinks and with three other reference transcript assembly algorithms (Scripture²⁹, IsoCEM²⁷ and SLIDE²⁸). We applied each program to the adrenal sample of the Human Body Map data and used our program ASprofile to extract exon skipping events from the assembled transcripts.

As the results in Table S6 indicate, when compared to Cufflinks, IsoCEM and SLIDE find roughly half the number of events, whereas Scripture finds roughly 60% more events. (Allowing for small differences, up to V bp, in the coordinates of introns and exons to account for imprecise mapping of splice junctions, has negligible effects on the comparison results). There is generally good agreement among the methods, as most of the events predicted with one method can also be retrieved by at least one of the other methods. In particular, 84% (2,471 out of 2,934) of the events predicted when using Cufflinks can be confirmed by other methods. Additionally, our analysis reveals a number of potentially new events, most of them discovered by Scripture, which could be used to enrich our repository in the future. However, each program has its own characteristics and biases, and a careful analysis has to be performed before incorporating these events into the database.

Table S5. Comparison of co-located ES events among the 26,989 events discovered from the Illumina Human Body Map data and the 25,114 exon skipping (ES) events extracted from the Ensembl v.61 annotations. *All* – all events co-located within *V* bp; *Loci* – clusters of co-located events (each with a representative ‘anchor’); *Var* (=All-Loci) – variations (not including ‘anchors’), representing potential mapping artifacts.

V	Cufflinks (26,989 events)				Ensembl 61 (25,114 events)				% Diff	Potential artifacts
	All	Loci	Var.	%	All	Loci	Var.	%		
1	647	300	347	1.29	90	45	45	0.18	1.10	298
2	1271	585	686	2.54	143	71	72	0.29	2.26	608
3	2394	1153	1241	4.60	530	262	268	1.07	3.53	953
4	3079	1476	1603	5.94	724	359	365	1.45	4.49	1210
5	3507	1685	1822	6.75	839	412	427	1.70	5.05	1363
6	3803	1832	1971	7.30	894	440	454	1.81	5.49	1483
7	3923	1890	2033	7.53	930	456	474	1.89	5.65	1523
8	4003	1929	2074	7.68	959	471	488	1.94	5.74	1549
9	4126	1991	2135	7.91	1020	502	518	2.06	5.85	1578
10	4192	2057	2135	7.91	1068	500	568	2.26	5.65	1524

Figure S5. Number of event variations due to small differences in exon and intron boundaries as a fraction of the total number of events, with varying cutoffs for the allowable difference (*V* bp). Values shown are for exon skipping (ES) events derived from the Illumina Human Body Map data (‘Cufflinks’) and from Ensembl v.61 gene annotations, from columns 4 and 8 in Table S5.

Table S6. Reproducibility of exon skipping (ES) discovery from transcripts assembled with different methods, and robustness with varying cutoffs (*V* bp) for the margin of error when comparing exon and intron boundaries.

Method	ES events	Found by other methods		
		V=0	V=5	V=10
Cufflinks	2,934	2,471	2,480	2,482
IsoCEM	1,486	1,361	1,364	1,365
SLIDE	1,418	860	884	895
Scripture	4,770	2,984	3,072	3,096

Figure S7. Histograms of reads in the 16 tissue samples supporting the two introns flanking the alternatively spliced exon (blue, red) and the intron spanning the exon (green), respectively, for the 26,989 identified exon skipping events. (A) Diagram of an exon skipping event, illustrating the three types of introns: left – blue, right – red, and intron spanning – green. **(B)** Read histograms for the three categories of introns. The x-axis represents the number of supporting reads for an intron, grouped in bins, and the y-axis shows the percentage of introns by levels of supporting reads (in bins).

Table S8. Summary of novel features by comparison to four annotation databases (CCDS, UCSC Genes, Ensembl v. 61, and H-DBAS). Exon and intron boundaries were compared allowing for a small difference (up to V=0, 5 and 10 bp). Values in bold are those reported in the main text.

Novel feature	V=0	V=5	V=10
Exon+Intron	2,518	1,430	1,214
Exon only	1,954	1,484	1,368
Intron only	13,531	14,528	14,726
Known	8,986	9,547	9,681

Figure S9. Novel exon skipping event at the human *ASB15* gene locus. Exon chr7:123,257,633–123,257,718, present in heart (heart.653543.1 and heart.653543.2) and with partial support in skeletal muscle tissue (skel_muscle.206929.2), is novel. Red arrows point to the exon appearing in two isoforms reconstructed in the heart sample, and to the (potentially) partial form in a skeletal muscle transcript for the *ASB15* gene. The spanning intron in the heart sample is also novel. Additionally, we found a potentially retained intron (chr7:123,269,489–123,270,019; thyroid.843995.1), circled in red, whose 531 bp sequence is conserved across multiple vertebrates.

Table S10. Exon skipping events expressed in each tissue sample, and number/percentage of these events that have only one expressed isoform in the sample.

Tissue	Events	Single variant
Adrenal	16,736	13,403 (80.1%)
Adipose	16,045	13,819 (86.1%)
Brain	17,415	13,865 (79.6%)
Breast	16,087	13,870 (86.2%)
Colon	13,802	12,464 (90.3%)
Heart	17,048	14,769 (86.6%)
Kidney	15,319	13,785 (90.0%)
Liver	12,390	11,388 (91.9%)
Lung	13,736	12,310 (89.6%)
Lymph	13,393	11,765 (87.8%)
Ovary	19,209	15,052 (78.4%)
Prostate	16,011	14,316 (89.4%)
Skel_muscle	10,160	9,614 (94.6%)
Testes	19,124	15,127 (79.1%)
Thyroid	18,689	14,362 (76.8%)
White_blood	12,954	12,017 (92.8%)

Figure S11. Expression levels of genes for the 13,946 events not comparable between adrenal and adipose tissues. 2,085 (15.0%) event genes are not expressed (FPKM<0.1), whereas 3,487 (33.7%) have FPKM values less than 10.0 and therefore may be incompletely reconstructed, which can cause a splice form to be missed.

Table S12. Variability of novel exon skipping events compared to known events. Novel events are depleted in ‘switches’ compared to known events (test of homogeneity, df=2, chi-square 274.7, p = 0.0).

Events	Stable	Variable	Switches	Total
Novel	1,788	5,334	10,320	17,442
Known	688	2,241	6,618	9,547
Total	2,476	7,575	16,938	26,989

Figure S13. Classes of alternative splicing events detected by ASprofile by pairwise transcript comparisons. (A) Exon skipping (SKIP) and cassette exons (MSKIP); (B) retention of single (IR) and multiple (MIR) introns; (C) alternative exon ends (AE); (D) alternative transcription start site (TSS); and (E) alternative transcription termination site (TTS). Alternatively spliced features are shown in red.

References

1.

Pan Q, Shai O, Lee LJ, *et al.*: Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. *Nat Genet.* 2008; 40(12): 1413–1415.
[PubMed Abstract](#) | [Publisher Full Text](#)

2.

Wang ET, Sandberg R, Luo S, *et al.*: Alternative isoform regulation in human tissue transcriptomes. *Nature.* 2008; 456(7221): 470–476.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

3.

Graveley BR: Alternative splicing: increasing diversity in the proteomic world. *Trends Genet.* 2001; 17(2): 100–107.
[PubMed Abstract](#) | [Publisher Full Text](#)

4.

Stamm S, Ben-Ari S, Rafalska I, *et al.*: Function of alternative splicing. *Gene.* 2005; 344: 1–20.
[PubMed Abstract](#) | [Publisher Full Text](#)

5.

Narla G, DiFeo A, Yao S, *et al.*: A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. *Proc Natl Acad Sci U S A.* 1999; 96(11): 6307–6311.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

6.

Narla G, DiFeo A, Yao S, *et al.*: Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. *Cancer Res.* 2005; 65(13): 5761–5768.
[PubMed Abstract](#) | [Publisher Full Text](#)

7.

Garcia-Blanco MA, Baraniak AP, Lasda EL: Alternative splicing in disease and therapy. *Nat Biotechnol.* 2004; 22(5): 535–546.
[PubMed Abstract](#) | [Publisher Full Text](#)

8.

David CJ, Chen M, Assanah M, *et al.*: HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. *Nature.* 2010; 463(7279): 364–368.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

9.

Hofstetter G, Berger A, Fiegl H, *et al.*: Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. *Oncogene.* 2010; 29(13): 1997–2004.
[PubMed Abstract](#) | [Publisher Full Text](#)

10.

Wheeler DL, Barrett T, Benson DA, *et al.*: Database resources of the National Center for Biotechnology Information. *Nucleic Acids Res.* 2008; 36(Database issue): D13–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

11.

Gerhard DS, Wagner L, Feingold EA, *et al.*: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). *Genome Res.* 2004; 14(10B): 2121–2127.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

12.

Wang Z, Gerstein M, Snyder M: RNA-Seq: a revolutionary tool for transcriptomics. *Nat Rev Genet.* 2009; 10(1): 57–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

13.

Mortazavi A, Williams BA, McCue K, *et al.*: Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nat Methods.* 2008; 5(7): 621–628.
[PubMed Abstract](#) | [Publisher Full Text](#)

14.

Gonzalez-Porta M, Calvo M, Sammeth M, *et al.*: Estimation of alternative splicing variability in human populations. *Genome Res.* 2012; 22(3): 528–538.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

15. Flicek P, Amode MR, Barrell D, *et al.*: **Ensembl 2012**. *Nucleic Acids Res.* 2012; **40**(Database issue): D84–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Pruitt KD, Harrow J, Harte RA, *et al.*: **The consensus coding sequence (CCDS) project: Identifying a common protein-coding gene set for the human and mouse genomes**. *Genome Res.* 2009; **19**(7): 1316–1323.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Dreszer TR, Karolchik D, Zweig AS, *et al.*: **The UCSC Genome Browser database: extensions and updates 2011**. *Nucleic Acids Res.* 2012; **40**(Database issue): D918–923.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Takeda J, Suzuki Y, Sakate R, *et al.*: **H-DBAS: human-transcriptome database for alternative splicing: update 2010**. *Nucleic Acids Res.* 2010; **38**(Database issue): D86–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Trapnell C, Pachter L, Salzberg SL: **TopHat: discovering splice junctions with RNA-Seq**. *Bioinformatics.* 2009; **25**(9): 1105–1111.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Trapnell C, Williams BA, Pertea G, *et al.*: **Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation**. *Nat Biotechnol.* 2009; **28**(5): 511–515.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Clark TA, Schweitzer AC, Chen TX, *et al.*: **Discovery of tissue-specific exons using comprehensive human exon microarrays**. *Genome Biol.* 2007; **8**(4): R64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Xu Q, Modrek B, Lee C: **Genome-wide detection of tissue-specific alternative splicing in the human transcriptome**. *Nucleic Acids Res.* 2002; **30**(17): 3754–3766.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. de la Grange P, Gratadou L, Delord M, *et al.*: **Splicing factor and exon profiling across human tissues**. *Nucleic Acids Res.* 2010; **38**(9): 2825–2838.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Elliott DJ, Grellscheid SN: **Alternative RNA splicing regulation in the testis**. *Reproduction.* 2006; **132**(6): 811–819.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Li Q, Lee JA, Black DL: **Neuronal regulation of alternative pre-mRNA splicing**. *Nat Rev Neurosci.* 2007; **8**(11): 819–831.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Sultan M, Schulz MH, Richard H, *et al.*: **A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome**. *Science.* 2008; **321**(5891): 956–960.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Li W, Feng J, Jiang T: **IsoLasso: a LASSO regression approach to RNA-Seq based transcriptome assembly**. *J Comput Biol.* 2011; **18**(11): 1693–1707.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Li JJ, Jiang CR, Brown JB, *et al.*: **Sparse linear modeling of next-generation mRNA sequencing (RNA-Seq) data for isoform discovery and abundance estimation**. *Proc Natl Acad Sci U S A.* 2011; **108**(50): 19867–19872.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Guttman M, Garber M, Levin JZ, *et al.*: **Ab initio reconstruction of cell type-specific transcriptomes in mouse reveals the conserved multi-exonic structure of lincRNAs**. *Nat Biotechnol.* 2010; **28**(5): 503–510.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. van Dijk TB, Gillemans N, Stein C, *et al.*: **Friend of Prmt1, a novel chromatin target of protein arginine methyltransferases**. *Mol Cell Biol.* 2010; **30**(1): 260–272.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. van Dijk TB, Gillemans N, Pourfarzad F, *et al.*: **Fetal globin expression is regulated by Friend of Prmt1**. *Blood.* 2010; **116**(20): 4349–4352.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. McDaniel TG, Hancock DL, Moody DE: **Altered mRNA abundance of ASB15 and four other genes in skeletal muscle following administration of beta-adrenergic receptor agonists**. *Physiol Genomics.* 2004; **16**(2): 275–283.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Singh RK, Cooper TA: **Pre-mRNA splicing in disease and therapeutics**. *Trends Mol Med.* 2012; **18**(8): 472–482.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Venter JC, Adams MD, Myers EW, *et al.*: **The sequence of the human genome**. *Science.* 2001; **291**(5507): 1304–1351.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Lander ES, Linton LM, Birren B, *et al.*: **Initial sequencing and analysis of the human genome**. *Nature.* 2001; **409**(6822): 860–921.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Richard H, Schulz MH, Sultan M, *et al.*: **Prediction of alternative isoforms from exon expression levels in RNA-Seq experiments**. *Nucleic Acids Res.* 2010; **38**(10): e112.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Derrien T, Johnson R, Bussotti G, *et al.*: **The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression**. *Genome Res.* 2012; **22**(9): 1775–1789.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Florea L, Di Francesco V, Miller J, *et al.*: **Gene and alternative splicing annotation with AIR**. *Genome Res.* 2005; **15**(1): 54–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 29 October 2013

<https://doi.org/10.5256/f1000research.2196.r2236>

© 2013 Robinson P. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peter N. Robinson

Institute for Medical Genetics, Universitätsklinikum Charité, Berlin, Germany

In this article, the authors address the question of how much alternative splicing can be identified in 16 different human tissues, and how much of the alternative splicing is specific for one or another tissue. To do so, they analyzed 50-bp paired-end sequences from 16 different tissue samples sequenced relatively deeply (ca. 80 million read pairs per tissue sample). The data has been made available by Illumina as the Human Body Map project. Computational analysis was then performed with the programs TopHat and Cufflinks. This type of analysis assembles the reads into a set of transcripts that are compatible with the splicing patterns inferred from reads that are split over multiple exons. Between 23,000–46,000 partial or complete transcript assemblies ("transfrags") were obtained per tissue. Approximately 5,000–20,000 transfrags per tissue, or 11–45% of the total, were identified as potentially novel splice forms. As the authors note, it is still difficult to assemble complete transcripts from relatively short RNA-seq reads in this way, and they thus make the very reasonable decision to concentrate their further analysis on alternative splicing events that are likely to be valid. Thus, it is easier to analyze the spectrum of exon skipping/inclusion events at a particular exon.

In general, the article is well done and will be of interest to those involved with RNA-seq or alternative splicing. One particularly interesting, if not entirely surprising, finding of this study is the fact that the majority of the novel exon insertion events showed a high degree of tissue specificity, thus providing an obvious explanation of why the corresponding exons are not yet in public databases. This suggests that efforts should be spent to characterize the full range of splicing in tissues in order to understand their biology.

Comments:

1. It would be useful if the authors could provide more discussion of the current state of the art of transcript identification using RNA-seq reads. In particular, the authors discuss three other transcript assembly programs in the supplement (S6), finding that they identify 50–60% of the isoforms called by Cufflinks. Have the authors performed their downstream analysis using the results of one of these programs? How different would the results be?

2. The authors should try to place their results in the context of many other efforts at identifying novel isoforms from the literature and discuss the relative merits of their approach.
3. It would be useful to have a table with quality metrics for this dataset, e.g., Phred scores, percent of mapable reads etc. - table S1 could be extended for this purpose.
4. Although much of the results deal with exon skipping/insertion events, it would be interesting to hear a little about results for other classes of alternative splicing that can be identified by the authors' software, e.g. alternative transcription start and termination sites.
5. In the results section, it would help the presentation of the material to provide a brief description of the relative inclusion ratio at this portion of the text and to define what i and j are (i.e., take some of the material from the methods section that explains this).

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 18 Nov 2013

Liliana Florea

We thank Peter Robinson for his insightful comments and suggestions, which we address in the following:

- Transcriptome assembly represents a complex topic on its own, and is only a tangent to our work, therefore we believe that it would be best addressed in detail elsewhere. We wish to point the reviewer and the readers to a review on current transcript assembly methods that we wrote recently, to appear in IEEE/ACM Transactions in Bioinformatics and Computational Biology journal. We also included a brief evaluation of several transcript assemblers on a simulated data set (new Table S2), showing that Cufflinks is the only program among those tested that can identify alternative splicing events with high enough accuracy (~90%) to allow meaningful downstream analyses, though we will explore combinations of these programs in the future. Minor correction to the statistic quoted by the reviewer: 84% of the Cufflinks-predicted exon skipping events are reproducible by other methods.
- There is indeed a rich body of work in the area of alternative splicing. Notably, two early studies (references 1 and 2) highlighted the extent of alternative splicing in the human genome based on analyses of RNA-seq data, albeit those data sets were not nearly large enough to be able to characterize it in detail, and a more recent study (Merkin *et al.*, 2012) extended those analyses in the context of multiple species. Similarly, there are now several methods (e.g., MISO, SpliceTrap and MATS) that infer or quantify exon skipping events directly from RNA-seq reads, and therefore are complementary to our approach. Using a very large data set, our work provides a more detailed picture of alternative splicing variation and produces both an easy-to-use tool and a database that we believe will be valuable in studies of alternative

splicing mechanism and function.

- We added percentage of mapped reads and number of properly paired reads to Table S1, as indicators of read alignment quality.
- We think that analyzing other types of events is indeed a very interesting experiment, which due to scale we plan to address in our future work.
- The definitions were already in the main text (page 7, section “Characterization of exon skipping events”), but we have clarified i and j.

Competing Interests: None

Reviewer Report 07 October 2013

<https://doi.org/10.5256/f1000research.2196.r1828>

© 2013 Corpas M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Manuel Corpas

The Genome Analysis Center, Norwich, UK

The article 'Thousands of exon skipping events differentiate among splicing patterns in sixteen human tissues' presents a systematic analysis of alternative splicing of the Illumina Body Map RNA-seq set, probably the most complete set of RNA-seq data to date. This data set consists of 160M reads each for 16 tissues, each from a different individual.

From the standpoint of a reviewer I consider this article to be of very good quality, and have very much enjoyed reviewing it. There are a few suggestions I hope could help improve this work.

1. P3. pp.2: Has alternative splicing profiling been attempted before? If so, could this please be shown in the background section? If not, how does this technique specifically differ from what has been done before? Some more context would be appreciated.
2. P3. pp.3: What is the effect of comparing tissues from 16 different individuals? I would expect that the genetic variation of each individual would have some effects in the actual AS patterns observed when compared. I see that these samples belong to people with different ethnic backgrounds and ages. I would be interested to know what the authors think about how different results would be if all 16 tissues had been from one individual.

3. I tried to compile ASprofile on a mac and I got this error:

libc.h:15:20: error: malloc.h: No such file or directory

I solved this by changing this line with `#include <stdlib.h>`. Perhaps you might want to add these lines, so that mac users do not encounter the problem:

```
#if !defined(__APPLE__)  
#include <malloc.h>  
#endif
```

4. Although the license for ASprofile is available in the Zenodo page, it might also be a good idea to mention it somewhere in the article. Not mentioning a license may make some users uneasy, even if it says it is open source.
5. In S1, how many of the mapped reads were properly paired?
6. Why did you use such old versions of Ensembl genes (Ensembl 61, February 2011), UCSC Genes, CCDS genes and H-DBAs? I also find that the TopHat (v1.3.3) and Cufflinks (v0.9.3) versions are quite old. The current version for TopHat is 2.0.9 and the current version for Cufflinks is 2.1.1. The current version of Ensembl is version 73, September 2013. The usage of such old versions concerns me a little, particularly those of the gene annotations, given that a lot of the results that are presented in this work rely heavily on the comparison of AS profiles against those annotations. Some of the results might be different if a newer version of the annotations were up-to-date.
7. P5. pp.5: The example of a novel event in CHTOP does not provide clear evidence as to how many reads support the novel exon. Please provide some numbers.
8. P7. pp1: Please could you provide evidence for the novel putative intron retention event located in the chr7:123269489-123270019 region?
9. In Figure S7.B, I would appreciate some text describing the biological significance of having the 100 bin in the x-axis with the greatest bars. Overall I am unable to understand what this figure means.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 18 Nov 2013

Liliana Florea

We wish to thank Manuel Corpas for his thorough review and suggestions. In responding to his comments:

- We would like to point to our answer to question 2 from Reviewer 1, where we more broadly address this and other related questions.
- An earlier study by Wang *et al.* (reference 2) also tackled polymorphic splicing

differences, finding that these represent a much smaller fraction of the AS variation compared to tissue differences. Therefore, while some polymorphic differences exist, they are not likely to distort the picture we paint in this study. We agree that analyzing data from multiple tissues in the same individual would be highly informative and we are actively looking for suitable data sets, which are not available at the moment.

- We thank the reviewer for taking the time to test the software. We updated the code and included a note on the license (GNU GPL) in the text (page 3).
- We have included proper read pairing information for all tissues in Table S1.
- With respect to the versions of the software, we note that at the time we ran our analyses we used the latest versions of each of these programs and databases, however our paper was caught up in the reviewing process at another journal for over a year. After two rounds of very slow reviews and multiple requests for revisions, the other journal was still not satisfied and therefore we decided to submit to F1000Research, which has far faster publication turnaround. We should emphasize that none of the previous reviewers' comments questioned the validity of our results, and our revisions did not substantively change any of our conclusions. Nevertheless, we also searched the 'novel' events against the aggregate set of Ensembl 73, GENCODE v.17 and RefSeq representing the most recent versions of these collections, and only found 21 exons and 9 introns (note that these did not include the events depicted in Figures 2 and S9). Hence, the results discussed in the manuscript still hold.
- We have added read support information for the exon skipping event in Figure 2, and for the putative intron retention event in Figure S9.
- The '100' bin in Figure S7 (now S8) shows the proportion of introns supported by more than 100 reads, for each of the three types of introns. Most events have deep support (≥ 100 reads) for the flanking introns, and to a lesser extent for the spanning intron, which is consistent with our earlier finding that the exon tends to be skipped in the minor form (Figure 3).

Competing Interests: None

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research